Deficiencies of folate or of vitamin B 12 are widespread and constitute a major global burden of morbidity affecting all age groups. Detecting or confirming the presence of folate or vitamin B 12 deficiency and distinguishing one from the other depends, ultimately, on laboratory testing. Tests to determine the presence of folate or vitamin B 12 deficiency are used singly or in combination to establish the nutritional status and prevalence of deficiencies of the vitamins in various populations. The efficacy of interventions through the use of fortification or supplements is monitored using the same laboratory tests. Tests currently in use have limitations that can be either technical or have a biological basis. Consequently, each single test cannot attain perfect sensitivity, specificity, or predictive value. Laboratory indicators of vitamin B 12 or folate status involve measurement of either the total or a physiologically relevant fraction of the vitamin in a compartment such as the blood. Thus, assays to measure vitamin B 12 or folate in plasma or serum as well as folate in red blood cells are in widespread use, and more recently, methods to measure vitamin B 12 associated with the plasma binding protein transcobalamin (holotranscobalamin) have been developed. Alternatively, levels of surrogate biochemical markers that reflect the metabolic function of the vitamin can be used. Surrogates most commonly used are plasma homocysteine, for detection of either vitamin B 12 or folate deficiency and methylmalonic acid for detection of vitamin B 12 deficiency. The general methods as well as their uses, indications, and limitations are presented.
Introduction and overview
There is a widespread global prevalence of folate and vitamin B 12 deficiencies, which gives rise to considerable morbidity [1] [2] [3] [4] . Because of the adverse consequences of such deficiencies, and the potential to prevent and correct them, the ability to assess folate and vitamin B 12 status is important for public health policy. Moreover, because the manifestations of frank deficiencies of folate or vitamin B 12 are identical and indistinguishable insofar as hematological complications are concerned, it is important to have a reliable means to discriminate diagnostically between the two vitamin deficiencies. Equally, it is important to be able to monitor the efficacy of intervention programs designed to eliminate or reduce the prevalence of deficiencies of these vitamins. In general, the methods to assess folate and vitamin B 12 status are the same as those used to monitor the efficacy of intervention programs. The tests' general usefulness (as well as their limitations) has been described in several reviews [1] [2] [3] [4] [5] [6] .
The methods used to assess folate and vitamin B 12 status fall into several categories that can be conveniently classified as those that directly measure the vitamins in the blood and those that measure metabolites which accumulate as a result of deficiencies of the vitamins required for their metabolism. In addition, deficiencies of folate or vitamin B 12 , when profound enough to cause disruption of normal cellular function with associated structural or morphological change, become evident through quantitative and qualitative changes in the blood. This topic is addressed in another report that is a part of these proceedings [7] . Additionally, there are less frequently performed tests that depend on demonstrating a biochemical lesion in short-term cultured cells (blood or bone marrow). This S53 Laboratory assessment of folate and vitamin B 12 deficiencies approach is used infrequently, primarily as a research tool, and will not be discussed here, as it is impractical for large-scale population screening for folate and vitamin B 12 deficiencies.
The ultimate proof that folate or vitamin B 12 deficiency is present, or that morbidity assigned to the presence of folate or vitamin B 12 deficiencies is indeed attributable to them, consists of demonstrating the reversal of those manifestations by administration of the appropriate vitamin in a dose, form, and duration that is adequate to correct the presumed deficiency. This is the basis of the "therapeutic trial" that was used to confirm folate or vitamin B 12 deficiency before specific tests became available to reliably make the diagnosis. Importantly, the dose should not vastly exceed the physiologic daily requirement, since nonspecific, including pharmacologic and mutually sparing, effects of folate and vitamin B 12 at higher doses can obfuscate distinctions between deficiencies of the two vitamins [4] . Although the "therapeutic trial" is no longer in use, ultimately, proof of the accuracy of diagnosis or of the efficacy of intervention resides in measurement or observation of a change in health outcome, either at the individual or at the population level. In essence, tests to assess folate or vitamin B 12 status can be used as surrogates for monitoring intervention, with one important caveat. The caveat is that correction of an "abnormal" laboratory value, in and of itself, does not necessarily connote successful outcome of the intervention, unless it is accompanied by objective improvement in the health of an individual or the disease prevalence in a population. Without such evidence, the "improvement" toward normality of a laboratory value provides no more than presumptive evidence of benefit. Development of tests suitable for screening for folate and vitamin B 12 deficiencies has occurred during the past half century, starting with measurement of the vitamins in the blood first by microbiologically based assays in the 1950s, then proceeding, in turn, to radioisotope competitive binding assays during the late 1960s and 1970s, followed by enzyme-linked and then chemiluminescent assays from the 1980s onward. The progressive evolution of these tests was driven by technology as well as by the relative ease and convenience of their performance, rather than by reliability. Thus, manually performed assay kits were replaced by automated tests. Rigorous considerations of accuracy or precision of the measurement or of the predictive value of the test for detecting deficiency seem not always to have been applied.
The adequacy of measuring vitamin levels in the blood as a means to reliably identify and distinguish folate and vitamin B 12 deficiencies is further affected and compromised by other factors [1, 2] . First, vitamin B 12 in circulation is associated with two distinct binding proteins. One binding protein, transcobalamin, binds only about 30% of total plasma B 12 ; however, it is known to play a critical role in the delivery of vitamin B 12 to cells. Therefore, even though transcobalamin binds a smaller fraction of the total plasma B 12 , it is considered to be functionally more important than the remaining portion bound to haptocorrin, and comprises approximately 70% of the plasma vitamin B 12 . Second, with respect to folate, plasma (or serum) folate shows diurnal and mainly prandial variation, reflecting recent food intake, whereas red blood cell folate remains stable and accurately reflects average body folate status at the time that the population of red cells was produced.
The alternative approach, namely that of measuring metabolites as surrogates for folate and vitamin B 12 deficiencies, had been proposed and was being used to a limited extent during the 1960s and 1970s. Mainly directed toward measurement of metabolites in the urine, these tests were generally laborious, and it was only in the 1980s, through the application of newer advances in analytical techniques such as high-pressure liquid chromatography and gas chromatography-mass spectrometry, that it became possible to measure precisely and with increased accuracy the levels of metabolites of interest in the blood. In this regard, two metabolites in particular, homocysteine and methylmalonic acid, emerged as being of greatest interest as indicators for the likely presence of metabolic deficiency of folate and vitamin B 12 [5, 6] .
Homocysteine is a sulfur-amino acid that requires both folate (in the form of 5-methyl-tetrahydrofolate) and vitamin B 12 (in the form of methylcobalamin) for one of its major pathways of disposal. In both folate and vitamin B 12 deficiencies, plasma homocysteine levels rise ( fig. 1) . Methylmalonate is a dicarboxylic acid that arises mainly from breakdown of certain amino acids and odd-carbon fatty acids. Vitamin B 12 is required in the form of deoxyadenosyl cobalamin for its conversion to succinate and subsequent reentry to the metabolic pool. Consequently, folate and vitamin B 12 deficiencies both give rise to elevations of plasma homocysteine, but of the two, only vitamin B 12 deficiency causes elevation of plasma methylmalonate [4] [5] [6] 8] . There are, however, other conditions, including renal failure, that cause elevation of homocysteine or methylmalonic acid or both in the plasma, as will be discussed [6] .
Through the use of these metabolite assays to distinguish folate from vitamin B 12 deficiency, it was proposed that elevated levels of metabolites constituted an early metabolic harbinger of depletion of these vitamins. This proposal was based on the premise that the deficiency had reached the point of disrupting cellular biochemistry, but had not yet resulted in either manifest stigmata of deficiency or in decrement of blood levels of the vitamins that were unequivocally below normal limits. This gave rise to the concept that biochemical deficiency, signaled by raised metabolite levels, provided the earliest, most sensitive means of S54 R. Green identifying folate and vitamin B 12 deficiencies [5, 8] .
More recently, in the case of vitamin B 12 , consideration has been given to the distribution of plasma cobalamin between its two binding proteins. Assays have now been developed to measure the transcobalamin-associated fraction of vitamin B 12 . Preliminary evidence indicates that this assay may offer the potential to enhance the predictive capacity for identifying vitamin B 12 deficiency, either alone or when used in conjunction with other available tests [9] [10] [11] [12] .
The choice of tests to assess folate and vitamin B 12 status and to monitor intervention depends on several considerations, including reliability, the setting in which the tests are used, and the availability and cost of the tests [3] . These considerations will be discussed further below.
Direct vitamin assays

Plasma or serum vitamin B 12
Following refinement of the microbiological assays for vitamin B 12 using either Lactobacillus leichmannii or Euglena gracilis, there was general satisfaction with the utility of these assays for diagnosing vitamin B 12 deficiency or assessing vitamin B 12 status. The labor-intensive nature of these tests, interference with the assay by drugs, and the advent of the more rapid and convenient radioligand binding assays in the clinical laboratory resulted in the virtual replacement of microbiological assays by radioligand binding assays. However, lack of specificity of binders other than intrinsic factor for cobalamin analogs resulted in spuriously high values for vitamin B 12 in some radioligand binding assays. Currently, all vitamin B 12 assays use intrinsic factor as the ligand-binding protein. Also, and as mentioned in the Introduction and Overview, radioisotope-based assays were supplanted by enzyme-linked immunoassays and chemiluminescent assays, which were developed by diagnostic companies and adapted to automated clinical chemistry instruments [13] .
Although measurement of the plasma or serum vitamin B 12 is, in the main, the most frequently used laboratory test to identify or exclude vitamin B 12 deficiency and to assess vitamin B 12 status in population screening, it is clear that the simple measurement of vitamin B 12 is beset by several problems. These problems range from poor specificity, in which individuals have low serum vitamin B 12 yet show no improvement in disease manifestations following treatment with vitamin B 12 , to the more serious instances of poor sensitivity, in which a vitamin B 12 assay fails to correctly identify individuals with well-characterized, clinically confirmed vitamin B 12 deficiency [14, 15] . There are several possible causes of the poor sensitivity and specificity of the plasma vitamin B 12 measurement. These are summarized in table 1. A recent report documented patients with objective responses to vitamin B 12 treatment despite apparently "normal" serum vitamin B 12 [16, 17] .
Previous reports have indicated that of all patients or individuals with clinical or metabolic evidence of vitamin B 12 deficiency, as many as 10% may have plasma Although it is not known with certainty why some patients with vitamin B 12 deficiency have normal vitamin B 12 concentrations, it is plausible that this may be explained, at least in part, by the distribution of vitamin B 12 between its two binding proteins in the plasma. As pointed out above, the major portion of the plasma vitamin B 12 is bound to haptocorrin and is considered unavailable for delivery of vitamin B 12 to cells. Consequently, a major fraction of the plasma vitamin B 12 is functionally inert so that even if the minor transcobalamin-bound fraction is depleted, the measured total vitamin B 12 value appears to lie within the normal range. The plausibility that distribution of vitamin B 12 among plasma binders explains the finding of an apparently normal plasma vitamin B 12 level in a vitamin B 12 -deficient individual is borne out by observations on those rare patients with congenital lack of transcobalamin. In this condition, which is associated with manifestations of severe vitamin B 12 deficiency, affected individuals frequently have plasma levels of vitamin B 12 that fall within the normal reference range [4] . Furthermore, in patients with high levels of haptocorrin, often found in association with increased white blood cell numbers, vitamin B 12 deficiency, as caused for example by coexistent pernicious anemia, may be present in the face of an apparently normal level of plasma vitamin B 12 [19, 20] . In theory, it should be possible to circumvent the misleading circumstance that approximately four-fifths of the total circulating vitamin B 12 that is measured as the plasma vitamin B 12 is not reflective of the functionally available vitamin B 12 compartment. Measurement of the vitamin B 12 bound to transcobalamin (holotranscobalamin or holo-TC) represents such an approach [21] , and assays have been developed to make this possible. These will be discussed later.
The converse problem of a lack of specificity of the plasma vitamin B 12 level for identifying vitamin B 12 deficiency-the "false positive" finding of a low plasma vitamin B 12 in an individual who is not vitamin B 12 deficient-may also be rooted in the distribution of vitamin B 12 on its binding proteins. In congenital haptocorrin deficiency, which, unlike transcobalamin deficiency, is a benign condition, the plasma vitamin B 12 level is usually low, frequently in the range considered indicative of vitamin B 12 deficiency [22] .
As with any measurement, the ability to discriminate "normal" from "deficient" with respect to identifying individuals who are at risk for developing disease associated with deficiency depends on the choice of the cutoff selected to define the lower limit of the normal reference range. There are two basic approaches that may be used. One is based on functional indicators of deficiency ("functional deficiency"), the other on disease indicators. Whether or not functional deficiency, if not corrected, invariably progresses to the ultimate expression of disease manifestations resulting from the deficiency is not known, nor is it known in what time frame such progression would occur. Collection of data on this important question is precluded by the unacceptability, for ethical reasons, of longitudinal studies without intervention to correct functional deficiency when it is first identified or sometimes merely suspected. Measuring plasma vitamin B 12 in a group of normal healthy individuals and applying standard statistical considerations to the data for the distribution is conventionally used to determine the normal reference range. Therefore, defining the reference range as the mean ± 2 SD implies that 5% of measurements among "normals" will lie outside the range. Thus, 2.5% will fall below the statistically defined reference range. If the reference range were to be extended to cover ± 3 SD, then the percentage of "normal" individuals with levels below the reference range would be considerably reduced. However, a substantial number of patients with true vitamin B 12 deficiency who have vitamin B 12 levels in the range of 148 to 221 pmol/L (200 to 300 pg/ mL) would not be identified, and the sensitivity of the plasma vitamin B 12 assay would thus be compromised. As is evident from this, adjusting the normal reference range has limited scope for improving the predictive value of the assay, because there is considerable overlap between the ranges encountered in the normal and 
S56
R. Green frankly deficient populations, as well as between the ranges encountered in the normal and functionally deficient populations. For the above reasons, attempts to improve the specificity of the plasma vitamin B 12 by lowering the lower limit cutoff for the "normal range" would result in a reduction in sensitivity, and conversely, raising the lower limit cutoff, while it would improve sensitivity, would come at the cost of an unacceptably high rate of false-positive values or loss of specificity. This statement applies also to the establishment of normal reference ranges for folate.
Plasma or red cell folate
Plasma and red cell folate measurements have been used routinely in the clinical laboratory as well as for epidemiological and population studies to screen for folate deficiency. As is the case with measurement of the plasma vitamin B 12 , measurement of plasma (or serum) folate was first carried out using microbiological assays. The organism of choice for the folate microbiological assay has been Lactobacillus casei, which shows growth response to all the major forms of folate in plasma. Streptococcus fecalis does not give a growth response to 5-methyl-tetrahydrofolate, which is the predominant chemical form of folate in the plasma. It is therefore possible to estimate methyltetrahydrofolate levels by measuring L. casei active folate and subtracting from it the S. fecalis active folate. As was the case with vitamin B 12 , microbiological assays for folate were soon replaced in turn by radioisotopic, enzyme-linked, and chemiluminescent assays. Within the past decade, measurement of red cell folate in material eluted from dried blood spots on filter paper has been reported [23, 24] . Such a method, if sufficiently robust, would lend itself to population studies, particularly those carried out in the field.
All of these various methods have been prone to problems of accuracy and precision, much of which has been attributable to methodological problems. As a result, the predictive value of folate measurements to identify deficiency has been seriously compromised. Plasma or serum folate less than 7 nmol/L (3 ng/mL) is indicative of negative folate balance, and if this state of negative folate balance persists for weeks or months, then morphological evidence of folate deficiency (megaloblastic changes in the blood and bone marrow) becomes evident [25] . Metabolic evidence of folate deficiency is, however, evident even at higher levels of plasma folate. In the Framingham population, Selhub et al. [26] reported that plasma homocysteine levels were significantly higher in the lowest two deciles of plasma folate (< 10 nmol/L) compared with the highest decile of plasma folate in that population. It has been reported that circulating levels of folate may be depressed in the face of apparently normal body folate stores following acute alcohol intoxication [27] .
In addition, a major limitation of the plasma or serum folate concentration as a measure of folate status was the observation that recent folate intake in a previously folate-deficient individual with normal absorptive capacity for folate could result in the misleading finding of an apparently normal plasma folate. Red cell folate, on the other hand, provides a more reliable index of folate status, since folate enters red cells only when they are developing in the bone marrow, and once inside does not significantly exit the red cell [4, 28] , so that red cell folate represents a stable reflection of the average level of folate repletion over the preceding 120 days (the average lifespan of red cells). Several studies have defined the lower limit of normal for the red cell folate concentration as 305 nmol/L (140 ng/mL), based on the appearance of disease indicators (morphological and/or biochemical evidence of megaloblastic hematopoiesis) [28, 29] .
For purposes of population surveys to assess folate status, measurement of plasma or serum folate alone does not allow for the distinction between a transient drop in folate intake and established chronic folate deficiency. On the other hand, folate in the plasma compartment is a reliable indicator of dietary folate intake. In interventional studies, single measurements of plasma or serum folate are not as reliable for assessing folate status as are red cell folate measurements [29] ; however, repeated plasma folate measurements over time in the same individual reflect trends in change of folate status.
Methodological issues relating to direct vitamin assays
With respect to both plasma (or serum) and red cell folate, and as is also the case with vitamin B 12 assays, for both clinical purposes and for population surveys, major reliance is now placed on kit-based assays. These are often automated or semiautomated assays supplied by commercial vendors. In the clinical arena, rigorous quality control and laboratory regulatory requirements in the United States and elsewhere require participation in mandatory proficiency programs. However, there have been reports of patients with disease indicators of vitamin B 12 deficiency whose measured circulating vitamin B 12 (serum or plasma) level fell within the normal reference range by a kit assay, yet who were clearly deficient by other assays [30, 31] . Also, there is a recent report that patients with apparent vitamin B 12 deficiency (based on clinical or hematological response to vitamin B 12 treatment) had "normal" vitamin B 12 levels before treatment [16] .
The most egregious example of a problem with folate kit assays occurred with a major US population survey (NHANES), in which it became known halfway through the study that the folate assay being used was calibrated with a folic acid standard that contained S57 Laboratory assessment of folate and vitamin B 12 deficiencies a lower amount of folate than initially stated, and resulted in an appreciable (30%) overestimation of the folate level in serum and red cells. This event, which occurred before folic acid fortification was introduced into the United States, necessitated the retrospective application of a correction factor to the assay results that had been carried out prior to the recognition of the error. Because of such inattention to requisite and essential quality control and test validation procedures on the part of some commercial kit manufacturers, and the fact that proprietary information regarding certain assay ingredients or design specifications sometimes precludes disclosure of the details of methodology, there is the distinct risk that spurious and misleading information can be generated that can seriously impact clinical as well as epidemiological and interventional studies. An international "round robin" on serum and red cell folate in distributed specimens reported substantial variations both between and within methods, particularly for red cell folate [32] . The recent development of "reference" specimens, validated by assays that are based on the accurate determination of stable-isotope or 14-carbon labeled standards by mass spectrometric methods, should prove helpful in regard to this problem in the future [33] .
Apart from methodological issues, there are other considerations that can potentially affect the reliability, clinical predictive value, or interpretability of assays for vitamin B 12 and folate in the blood. In the case of the plasma vitamin B 12 , it has already been pointed out that the distribution of vitamin B 12 between the two major binding proteins may exercise a substantial and significant effect on the level of the circulating vitamin, and hence the correlation between a measured value of plasma vitamin B 12 and vitamin B 12 status. Additionally, in all of the methods to measure vitamins in the blood, including vitamin B 12 and folate, it is essential that the vitamin be able to be completely and reproducibly extracted, intact, from its binding or association with proteins or other molecules. The vitamin then needs to be conserved in a stable form that can be detected by the particular method in use, and give dose-equivalent responses to suitable calibrated standards in that detection method. Whether these criteria are met has, at times, been questioned for particular methods.
It is with the red cell folate assay in particular that the issues of adequacy of extraction and form of assayable material have been brought forward as potential in currently designed red cell folate assays. Specifically, questions have arisen with regard to the method of preparation of hemolysates for assay, and in particular, the timing of addition of ascorbate or other reducing agent. Also, the form of folate used as assay calibrant, and the equivalency of its binding to the ligand binder used in the assay compared with that of the extracted folate from the specimen, is a potential source of discrepancy between results obtained on the same speci-men by different assays [34] . It has been proposed that whereas deoxyhemoglobin binds folate electrostatically in red cells and oxyhemoglobin does not [35] , this can result in less assayable folate when oxyhemoglobin levels are relatively increased. Theoretical ways to overcome this potential problem have been proposed, including equilibration under anaerobic conditions (e.g., nitrogen gas) or the addition of powerful allosteric effectors to lower hemoglobin oxygen affinity. None of these methods have, however, been incorporated into a novel red cell folate assay [36] .
Finally, and with respect to both folate and vitamin B 12 , it is now clear that several common polymorphisms of enzymes or binding proteins related to vitamin B 12 and folate metabolism affect the levels of these vitamins in the plasma, and in the case of folate, also in the red cells. Most notably, in both pregnant and nonpregnant women, the common C677T polymorphism of methylenetetrahydrofolate reductase was reported to be associated with lower red cell folate levels (TT significantly lower than CT heterozygotes and CC homozygotes), and in the case of pregnant women, plasma folate was also lower in TT individuals compared with those with the CC genotype [37] . The MTHFR genotype also influences the folate and homocysteine response to folate intake and folic acid supplementation [38] [39] [40] . With respect to the common polymorphism of transcobalamin, C776G, several studies have confirmed that the GG genotype is associated with lower levels of holotranscobalamin either with [41] or without [42, 43] higher levels of methylmalonate and homocysteine compared with CC individuals [41] [42] [43] .
Surrogate metabolite assays
As pointed out in the Introduction and Overview, development of sensitive and reproducible assays for the major metabolites that are known to accumulate in folate and vitamin B 12 deficiency enabled the application of these methods for clinical use, and for distinguishing folate from vitamin B 12 deficiencies. Also, because of the fact that any interference or interdiction of the folate-and vitamin B 12 -dependent reactions required for onward metabolism of the metabolites should, theoretically, result in accumulation of those metabolites with consequent elevation of their levels in the blood, it was logical to anticipate that elevation above the normal range could provide very early evidence of functional deficiency of the vitamins. That this was indeed the case soon became evident from several landmark studies that were shortly confirmed by a number of subsequent reports. The two major metabolites that emerged as being of primary utility with respect to identifying and distinguishing vitamin B 12 and folate deficiencies are homocysteine and methylmalonic acid. This primary choice of metabolites S58 R. Green arises from the fact that of the two vitamins, B 12 alone is required for conversion of methylmalonate to succinate. Folate is not involved in this reaction. Therefore, methylmalonate levels are raised only in vitamin B 12 but not in folate deficiency. On the other hand, both folate and vitamin B 12 are necessary for metabolism of homocysteine through one of its major routes of metabolism, and consequently plasma homocysteine levels are elevated in both vitamin B 12 and folate deficiencies. There is no known, conveniently measurable metabolite that becomes elevated in folate deficiency only but not also in vitamin B 12 deficiency. In summary, therefore, an elevation of methylmalonate alone favors vitamin B 12 deficiency, whereas an elevation of homocysteine could be indicative of either folate or vitamin B 12 deficiency. However, and as detailed in the following sections, elevated levels of methylmalonate or of homocysteine also occur in several other conditions, in the absence of either vitamin B 12 or folate deficiency. Despite this caveat, the metabolite assays have great utility for several purposes that relate to vitamin B 12 and folate deficiencies. The applications of metabolite assays in the context of vitamin B 12 and folate deficiencies include the following: » For primary identification of vitamin B 12 It is important to recognize the limitations of the metabolite assays. Specifically, the raised levels of metabolites constitute only presumptive evidence of an underlying vitamin deficiency, and cannot be equated with clinical vitamin B 12 (or folate) deficiency [44] . Metabolic evidence alone may indicate that impairment of health and well-being attributed to an underlying vitamin deficiency was in fact caused by the deficiency, but only if the administration of vitamin B 12 or folate to such individuals results in correction of their metabolic derangement. This, however, connotes presumptive evidence only that a state of suboptimal vitamin nutrition existed prior to vitamin B 12 or folate administration. The mere accumulation of a metabolite does not, however, constitute evidence that the metabolites per se are ultimately responsible for any dysfunction or disease that may be associated with clinically identifiable vitamin B 12 or folate deficiency. Moreover, the lowering of metabolite levels, whether or not they were elevated, by the administration of vitamin B 12 or folate, does not constitute a priori evidence that a state or condition of deficiency of either of the vitamins existed and that resulted in morbidity. Lowering of a metabolite level, although it may be associated with amelioration of the manifestations of an existing underlying vitamin deficiency, does not constitute proof of a cause and effect relationship between the elevated metabolite level and the particular manifestations of the deficiency. The alleviation of both the manifestations of the deficiency and the raised metabolite may be coincidental and relate to an upstream cause of both. In this case, correction of the upstream cause would correct both the disease state and the abnormal metabolite level.
Plasma homocysteine
A number of approaches have been developed for measurement of plasma homocysteine. These include high-pressure liquid chromatography (HPLC), gas chromatography mass spectrometry (GCMS), radioenzymatic assays, and immunoassays. This subject has been comprehensively reviewed recently [45] . Recently, a screening method has been described for detecting raised plasma homocysteine using dried blood spots that uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) [46] . This method could prove useful for field studies using small-volume specimens.
Although not yet applied to an assay method, a potential colorimetric assay has been proposed in which a thiazolidine derivative of homocysteine is formed [47] . With respect to plasma homocysteine measurement, it is important to separate the plasma from red cells as soon as possible following the withdrawal of a blood sample to avoid in vitro exchange between the plasma and cellular compartments or cellular metabolism of homocysteine. Serum homocysteine is higher than plasma homocysteine, and this difference increases the longer the time allowed for clotting of a blood specimen for serum collection [45] .
Homocysteine is derived almost entirely through metabolism of dietary methionine. However, the plasma homocysteine level apparently is not directly related to dietary composition with respect to its methionine content. This may be explained by dietary associations with several other nutrients that influence homocysteine as well as regulatory effects of methionine cycle intermediates on methionine cycle enzymes. This complicates the expected direct relationship between plasma homocysteine and methionine intake through dietary sources. The dietary factors include the B vitamins involved in homocysteine metabolism and, in particular, vitamin B 12. Thus, vegetarians are found to have higher rather than lower plasma levels of homocysteine than nonvegetarians. The second factor that is responsible for obscuring a direct relationship between methionine intake and plasma homocysteine S59 Laboratory assessment of folate and vitamin B 12 deficiencies is the coordinate allosteric regulation of methionine metabolism by adomet (S-adenosyl methionine or SAM) at two key steps in the pathway [48] (fig. 1) . Adomet exerts a positive allosteric effect on the enzyme cystathionine β−synthase that is responsible for metabolism of homocysteine through transsulfuration, one of its major routes of disposal. The other effect of adomet is a negative allosteric regulation of MTHFR which reduces the formation of methyltetrahydrofolate, the cosubstrate for homocysteine in its remethylation to methionine.
Raised levels of homocysteine in the circulation (hyperhomocysteinemia) are important not only as a surrogate indicator of possible underlying vitamin B 12 or folate deficiency, but also as an independent risk factor for cardiovascular [6] and other disease. Examples include osteopenia [49] [50] [51] and Alzheimer's disease [52, 53] . There are several causes of raised plasma levels of homocysteine (table 2). These can be grouped into the general categories of demographic and lifestyle, nutritional, metabolic, genetic, and drug causes. Among the demographic and lifestyle factors, homocysteine rises with increasing age, and men have higher levels than women. The gender relationship appears to relate to hormonal factors in that the gender gap narrows following the menopause. Also, lean body mass affects homocysteine because of the requirement for methionine in the form of adomet for creatine synthesis [54] .
Folate and vitamin B 12 deficiencies are important among the nutritional causes of raised homocysteine levels, and on a global basis, are major causes of mild to severe hyperhomocysteinemia. In population surveys, multivariate models suitably controlled for other variables have found that the population-attributable risk (PAR) of hyperhomocysteinemia related to folate status is high, accounting for around 25% in populations not consuming a diet fortified with folic acid or receiving supplemental folic acid. In contrast, where folic acid fortification has been introduced, such as in the United States and in Canadian populations, the PAR for hyperhomocysteinemia caused by folate is around 1%. On the other hand, in such populations the PAR for hyperhomocysteinemia related to vitamin B 12 status is now around 20% to 25%, making vitamin B 12 the commonest modifiable cause of hyperhomocysteinemia [55, 56] .
The extent of elevation of the homocysteine in vitamin deficiencies varies continuously with the degree of deficiency from mild to severe, so that there is generally an inverse correlation between the homocysteine and the vitamin measurement within the population overall. However, within the normal range of vitamin concentrations, and except for the lower limit of the normal range, homocysteine concentrations show little discernible variation [26] . In individuals with plasma folate or vitamin B 12 levels in the deficient range, and evidence of clinical deficiency of the vitamins, homocysteine rises steeply [26, 57] . In individuals with severe folate or vitamin B 12 deficiency, degrees of hyperhomocysteinemia comparable to those seen in patients with homocystinuria (in the range of 300 µmol/L) may be found [6] . Despite the generally good correlation between circulating homocysteine levels and both vitamin B 12 and folate status, there are important caveats with respect to the use of plasma homocysteine levels as a surrogate for detection, confirmation, or discrimination of either folate or vitamin B 12 deficiencies. The first of these relates to the poor specificity of raised homocysteine as an indicator of folate or vitamin B 12 status. There are multiple other causes of raised homocysteine that need to be considered and excluded when homocysteine is used as a surrogate for either vitamin B 12 or folate status (table 2). In an individual subject or patient, a homocysteine value cannot be reliably used in isolation to identify either vitamin B 12 or folate deficiency. In the population setting, before attributing change in a dependent variable or parameter to any particular independent variable, it is essential to conduct statistical analysis using a multivariate model that takes due consideration of confounders and makes appropriate adjustments for them. This consideration applies to the use of plasma homocysteine (dependent variable) to the independent variable (reflecting objective evidence of folate or vitamin B 12 deficiency).
With respect to other causes of hyperhomocysteinemia, the metabolic causes are important to consider and exclude in clinical settings, or appropriately correct for in population studies. This applies in particular to renal disease because of its high prevalence in older individuals. The same also applies, though to a lesser extent in terms of frequency, to hypothyroidism [5, 6] . With respect to genetic causes, homozygosity for deletions or mutations of genes for methionine cycle or transsulfuration pathway enzymes (including folate cycle or cbl mutants that are associated with functional inactivity of the corresponding enzyme) can produce severe hyperhomocysteinemia and homocystinuria, usually at a young age. However, heterozygosity and even homozygosity for the common genetic polymorphisms of enzymes involved in homocysteine metabolism, including MTHFR, cystathionine β−synthase, and methionine synthase reductase, generally produce only mild degrees of hyperhomocysteinemia, and often only when the individual has deficient plasma levels or suboptimal status of the vitamins involved in the reactions catalyzed by these enzymes. This is particularly the case with regard to MTHFR and folate status [6] .
With the above caveats, as well as the general considerations of the limitations that apply to use of metabolite measurements as surrogates for assessing vitamin status referred to above, the evidence that links raised homocysteine levels with deficiencies of vitamin B 12 or folate is summarized below. Full review of the many population studies that have been carried out to assess the prevalence of hyperhomocysteinemia and its potential role as a risk factor in cardiovascular disease lies beyond the scope of this review. Such studies include cross-sectional, case-controlled, and prospective studies, and frequently include simultaneous measurement of the known determinants of plasma homocysteine, including vitamin B 12 and folate status. The focus of these studies is primarily the use of homocysteine as a marker for cardiovascular damage, and only secondarily examines the potential determinants of the homocysteine level, including vitamin B 12 and folate status. These studies have been analyzed in several meta-analyses [58, 59] .
Plasma or serum methylmalonate
Currently, the standard method used for measurement of plasma or serum methylmalonate involves a derivatization followed by gas chromatography-mass spectrometry (GCMS). No other robust methodology has been developed that provides the sensitivity and precision attained by GCMS, which is necessary for measurement of the low concentrations of methylmalonate present in the plasma. Requiring sophisticated equipment, this methodology is generally restricted to specialized reference laboratories at the present time [60] [61] [62] . Methylmalonate is derived from the degradation of odd-carbon fatty acids as well as catabolism of ketogenic amino acids [63] . The metabolism of methylmalonate requires its conversion to methylmalonyl CoA and then to succinyl CoA, through a mitochondrial enzyme that requires vitamin B 12 in the form of adenosylcobalamin. Folate is not required for this reaction; hence levels of methylmalonate in the plasma and urine rise only in vitamin B 12 deficiency but not in folate deficiency.
There are, however, other causes of an elevation of plasma methylmalonate besides vitamin B 12 deficiency, including impairment of renal function often detected by elevated serum creatinine [64] . As with homocysteine, methylmalonate levels vary continuously with the degree of vitamin B 12 deficiency. Overall, there is an inverse correlation between plasma vitamin B 12 and methylmalonate. There is an inflection point in the curve that describes the relationship of vitamin B 12 to methylmalonate. This point may be used to determine the level of vitamin B 12 below which there is a metabolic effect of the deficiency [57] . Though relatively specific and sensitive for the detection of B 12 deficiency, measurement of methylmalonate is now somewhat restricted through considerations of cost and accessibility in developing countries. Measurement of urine methylmalonic acid has been in clinical use as a surrogate for plasma methylmalonate for diagnosis of vitamin B 12 deficiency [65] , and a method has been described using filter paper urine samples for measurement of methylmalonic acid using stable-isotope dilution GC-MS [66] . However, this approach has not been applied to population screening.
Other metabolites
Other metabolites have been used to identify and distinguish vitamin B 12 from folate deficiency. These methods are not in widespread use and lie beyond the scope of the present report [8] .
Measurement of holotranscobalamin
As pointed out above, only the fraction of vitamin B 12 attached to transcobalamin is functionally important, and methods are now available to measure this fraction. In the past, the use of holotranscobalamin (holo-TC) measurement for assessment of vitamin B 12 status was severely compromised by technical limitations in the assay. Earlier assays all suffered from the drawback that holo-TC levels, rather than being measured directly, were calculated by determining the difference between a total plasma vitamin B 12 measurement and a measurement of residual vitamin B 12 left after removal of TC-bound B 12 by adsorption to either microfine silica or a bead coated with antibody to TC. More recently, assays capable of directly measuring the small holo-TC fraction have been developed [67, 68] . Several studies have reported the clinical and epidemiological utility of holo-TC measurement for detection of vitamin B 12 deficiency or vitamin B 12 status determination for population screening [9] [10] [11] [12] [69] [70] [71] [72] . These data suggest that the measurement of holo-TC provides an alternative to measurement of total vitamin B 12 as an index of vitamin B 12 status, and in general, these studies indi-S61 Laboratory assessment of folate and vitamin B 12 deficiencies cate that used singly, holo-TC measurement is about equivalent to total serum vitamin B 12 with respect to sensitivity and specificity. Additionally, however, it appears that measurement of holo-TC in conjunction with vitamin B 12 improves the predictive value for identifying true vitamin B 12 deficiency [12] .
Summary and conclusions
Assessment of folate or of vitamin B 12 status is a prerequisite for determining the prevalence of deficiencies of these vitamins in populations, and for devising suitable strategies to prevent or remedy these nutritional problems. Deficiency of these related vitamins accounts for a substantial burden of morbidity around the world. They afflict all age groups, and are known to be responsible for a variety of disease states as well as being associated with and suspected of playing a role in others. Detecting or confirming the presence of folate or vitamin B 12 deficiency, and distinguishing one from the other, essentially depends on laboratory testing. Screening tests to determine the presence of folate or vitamin B 12 deficiency are used singly or in combination to establish the nutritional status and prevalence of deficiencies of the vitamins in population groups.
The efficacy of interventions through the use of fortification or supplements is also best monitored using such laboratory tests. Laboratory indicators of vitamin B 12 or folate status typically involve measurement of either the total or a physiologically relevant fraction of the vitamin in the blood. Alternatively, measurements of surrogate biochemical markers are used that reflect the metabolic function of the vitamins, homocysteine for detection of either vitamin B 12 or folate deficiency, or methylmalonic acid for detection of vitamin B 12 deficiency. It is frequently the case that individual tests lack sensitivity, specificity, or predictive value, so that various tests are frequently combined in testing strategies. The uses and limitations of available laboratory methods to assess folate or of vitamin B 12 status have been reviewed.
